Renzenbrink & Partner advised pan-European private equity investor Apheon on Unigestion\u2019s acquisition of a minority stake in its portfolio company Ortivity.<\/p>\n\n
Founded in 2022 by a group of leading physicians, Dr. med. Reinhard Wichels and Apheon, Ortivity is Germany\u2019s leading integrated outpatient care platform for orthopaedic services. The company operates more than 100 medical centres across three regional clusters, offering a full range of orthopaedic treatments including diagnostics, anaesthesia, surgery, prevention, and aftercare. With its physician partnership model and strong emphasis on clinical excellence, Ortivity has established itself as a trusted provider and enabler of modern outpatient infrastructure. <\/p>\n\n
Through its private equity funds, Unigestion has acquired a significant minority stake in Ortivity alongside selected Apheon investors, while Apheon remains the lead investor. The transaction strengthens the company\u2019s capital base and supports its strategic growth plans, including the expansion of existing regional clusters and the establishment of new ones, aiming to advance Germany\u2019s transition to a modern outpatient orthopaedic care model. <\/p>\n\n
Renzenbrink & Partner advised Apheon as lead counsel, in particular on the structuring and negotiation of the transaction documentation and all corporate aspects of the investment.<\/p>\n\n
The Renzenbrink & Partner team comprised Dr. Ulf Renzenbrink<\/a> (Corporate\/Private Equity), Christopher Blumenthal <\/a>(Corporate\/M&A) and Dr. Alexander Haunschild<\/a> (Corporate\/M&A) as well as Marc Kotyrba<\/a> (Tax\/Private Equity). <\/p>\n\n <\/p>\n","protected":false},"featured_media":2127,"template":"","class_list":["post-2128","deals","type-deals","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n